For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of GLP-1/amylin agonist amycretin that achieved reductions of between 10.4% and 13.1% in ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Q2 2025 Earnings Call Transcript August 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0 ...

Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug ...

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Eli Lilly’s new weight-loss daily pill underperformed against competitors in weight... The Competition and Consumer Protection Commission (CCPC) has found that there is... Bank of Ireland has ...

Eli Lilly’s potential obesity pill helped patients lose less weight than investors had hoped during a trial, sending shares in the drugmaker down as much as 12 per cent in pre-market trading.

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...